Skip to main content

Table 3 Bowel Habit Survey

From: Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients

Variables Baseline to week 4 Baseline to week 12
  Improvement rate P-value Improvement rate P-value
Decrease in stool frequency among those reporting change 18/28 (64.3%) 0.13 18/32 (56.3%) 0.48
Improved stool consistency among those reporting change 23/30 (76.75%) 0.004 19/27 (70.4%) 0.03
Decrease in stool volume among those reporting change 11/16 (68.8%) 0.13 8/13 (61.5%) 0.41
Resolution of blood in stool among those reporting change 5/6 (83.3%) 0.10 4/6 (66.7%) 0.41
  Baseline to week 4 (n = 70) Baseline to week 12 (n = 62)
Overall change in bowel habit score (BHS) [mean (SD)] -0.281 ± 0.719 0.002 -0.227 ± 0.707 0.01
  1. Self-reported bowel habit score (BHS) was assessed on a scale in which stool consistency was (solid = 1, loose = 3, watery = 5); volume (small = 1, moderate = 3, large = 5), blood (no = 1, yes = 5); Frequency (1 - 5). For example, a subject with baseline responses of: Solid, Moderate, no blood, and frequency of "2" would have a score of: (1 + 3 + 1 + 2)/4 = 1.75 for their baseline summary score. Therefore the scale has a minimum of 1 (best BHS outcome) and a maximum of 5 (worst BHS outcome); SD, standard deviation.